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ABSTRACT
Purpose To study the function and expression of nine natu-
rally occurring single-nucleotide polymorphisms (G406R,
F431L, S441N, P480L, F489L, M515R, L525R, A528T
and T542A) that are predicted to reside in the transmem-
brane regions of the ABC transporter ABCG2.
Methods The transport activity of the variants was tested in
inside-out membrane vesicles from Sf9 insect and human de-
rived HEK293 cells overexpressing ABCG2. Lucifer Yellow
and estrone sulfate were used as probe substrates of activity.
The expression levels and cellular localization of the variants
was compared to the wild-type ABCG2 by western blotting
and immunofluorescence microscopy.
Results All studied variants of ABCG2 displayed markedly
decreased transport in both Sf9-ABCG2 and HEK293-
ABCG2 vesicles. Impaired transport could be explained for
some variants by altered expression levels and cellular locali-
zation. Moreover, the destructive effect on transport activity
of variants G406R, P480L, M515R and T542A is, to our
knowledge, reported for the first time.
Conclusions These results indicate that the transmembrane
region of ABCG2 is sensitive to amino acid substitution and
that patients harboring these ABCG2 variant forms could
suffer from unexpected pharmacokinetic events of ABCG2
substrate drugs or have an increased risk for diseases such as
gout where ABCG2 is implicated.
KEY WORDS BCRP. genetic variant . interindividual
variability . pharmacogenetics . SNP
ABBREVIATIONS
ABC ATP-binding cassette
BCRP Breast cancer resistance protein
E1S Estrone sulfate
HEK293 Human embryonic kidney cell line
LY Lucifer yellow




The transporter ABCG2, often referred to as the breast can-
cer resistance protein (BCRP), is a member of the ATP-
binding cassette (ABC) transporter family. ABC transporters
are membrane proteins that use ATP to exclude a diverse
range of molecules including endogenous metabolites and xe-
nobiotics from cells. The ABCG2 gene, located in chromo-
some 4, encodes a 655 amino acid long peptide chain that
forms an intracellular N-terminal ATP-binding domain
followed by six transmembrane helices. The detailed organi-
zation in the cell membrane remains to be elucidated since
there is no available crystal structure of ABCG2. The struc-
ture of ABCG2 is different from typical ABC-transporters that
have 12 or more transmembrane helices and two ATP-
binding domains. Due to its Bhalf-transporter^ structure,
ABCG2 has to form dimers to exert its transport function,
but it has also been suggested to function as tetramers or
higher order oligomers (1,2).
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Transmembrane Domain Single-Nucleotide Polymorphisms
Impa i r Expres s ion and Transpor t Act i v i t y o f ABC
Transporter ABCG2
Expression of ABCG2 in cancer cells increases resistance to
several chemotherapeutic agents such as mitoxantrone,
topotecan and methotrexate (3–5). Due to its localization in
the intestine, liver and kidneys (4,6), ABCG2 increases elimi-
nation of substrate drugs and decreases absorption and bio-
availability. ABCG2 also has a protective role in limiting dis-
tribution of xenobiotics in distinct organ compartments such
as the brain and placenta (4,7). In addition to transporting
drugs and toxins, ABCG2 disposes of endogenous metabo-
lites, including estrogen metabolites (8). ABCG2 is one of
the transporters involved in uric acid transport in the body
and dysfunction of ABCG2 is shown to be related to gout risk
(9,10). On the other hand, ABCG2 null alleles have been
linked to a Junior (a-) blood group phenotype that results in
adverse effects in blood transfusions (11). It is suggested that
ABCG2 and its variant forms could also be involved in pho-
tosensitivity, since it is involved in cellular porphyrin homeo-
stasis (12). In addition to this, manymore xenobiotic substrates
as well as a plethora of inhibitors have been identified in in vitro
studies, whichmeans that there is a great potential for unwant-
ed ABCG2-mediated pharmacokinetic events. A decrease in
ABCG2 transport activity arising from interindividual genetic
variations or inhibition can result in unexpectedly high con-
centrations of substrate drugs due to increased absorption and
decreased elimination.
Nonsynonymous single-nucleotide polymorphisms (SNPs)
introduce an amino acid change in the peptide sequence,
which can alter the expression, function or localization of
the proteins they encode. Genotyping studies of ABCG2 have
revealed several hundred naturally occurring nonsynonymous
SNPs (424 variants listed in the Ensembl GRCh37 database,
release Oct2016). The majority of these variants occur at a
frequency of < 1% in most populations. The most common
variants are V12M and Q141K, which cause amino acid
changes in the intracellular regions of ABCG2. They occur
at a frequency of 19.2% and 31.9%, respectively, in the
Japanese population (9), but are rarer in other populations,
with the Q141Kminor allele frequency being roughly 10% in
Caucasians and 3% in blacks (10,13). In addition to being
linked to gout (9,10), the Q141K variant alters pharmacoki-
netics of atorvastatin, rosuvastatin and sulfasalazine (13,14).
The decreased transport of Q141K, observed to be around
50% of wild-type (WT) ABCG2 in in vitro studies, can be
explained by reduced plasma membrane expression
(9,15–17). The other common variant, V12M, does not ap-
pear to confer changes in expression level or function of
ABCG2 (9,12,15–17).
An acquired transmembrane domain SNP, resulting in the
change of R482 to threonine or glycine, was identified in
several cancer cell lines in vitro. It has received considerable
interest, because it was shown to be a gain-of-function muta-
tion leading to increased mitoxantrone and doxorubicin resis-
tance compared to the WT as well as the ability to transport
daunorubicin, rhodamine 123 and LysoTracker green, unlike
WTABCG2 (18–20). Discovery of the R482 mutant lead to a
number of mutational studies on other transmembrane resi-
dues and decreased transport function of mitoxantrone resis-
tance has been linked for example to changes at positions 336,
557 and 630 (19). These results indicate that changes in the
transmembrane helices of ABCG2, which line the substrate
binding cavity, can have a significant effect on substrate
recognition.
Here we present the function and expression of nine natu-
rally occurring SNPs (G406R, F431L, S441N, P480L, F489L,
M515R, L525R, A528T and T542A) that are predicted to
reside in the transmembrane domains of ABCG2 and were
therefore hypothesized to impact ABCG2 transport activity
(Fig. 1, Table I). Indeed, we found that all nine studied vari-
ants had impaired substrate transport that could not be ex-
plained solely by expression levels. Patients harboring these
variants may thus experience altered pharmacokinetics of




[3H]-estrone sulfate ammonium salt (E1S; 54 Ci/mmol) was
purchased from Perkin Elmer (Boston, MA, USA). Fetal bo-
vine serum (FBS) and DMEM were from Gibco (Invitrogen,
NY, USA) and HyClone SfX Insect cell medium from
Thermo Fisher Scientific (Waltham, MA, USA). Lucifer yel-
low CH dipotassium salt (LY), unlabeled E1S and all other
chemicals were from Sigma-Aldrich (St. Louis, MO, USA)
un l e s s s t a t ed o the rw i s e . Mu tagene s i s p r ime r s
(Supplementary 1) were produced by Oligomer (Helsinki,
Finland).
Preparation of Plasmids Carrying ABCG2 Variant
Forms
The pFastBac1-BCRP vector and pENTR221-hBCRP en-
try vector for Gateway cloning were constructed as de-
scribed previously (23,24). The SNPs were incorporated
into the ABCG2 gene in these vectors using the Q5 site-
directed mutagenesis kit (New England Biolabs Inc.,
Ipswich, MA, USA) except for the 1582 G > A which was
produced using the Q5 polymerase (New England Biolabs
Inc.) and overlapping primers. DpnI (Thermo Fisher
Scientific) was used to digest the template DNA. The pres-
ence of the SNPs was verified by sequencing the whole
ABCG2 gene using the sequencing service from GATC
Biotech (Constance, Germany). The ABCG2 WT and var-
iant genes were transferred from the pENTR221-hBCRP
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entry vector to a modified Bac-to-Bac vector using
Gateway cloning (Invitrogen). Recombinant baculoviruses
for both Sf9 and HEK293 expression were generated ac-
cording to the Bac-to-Bac protocol (Invitrogen Life
Technologies, Carslbad, CA, USA). A vector containing
the gene for enhanced yellow fluorescent protein (eYFP)
was used as a control in the HEK293 expression system
and an empty bacmid served as a control in the Sf9 system.
Fig. 1 Predicted localization of the studied single-nucleotide polymorphisms in the transmembrane regions of ABCG2. The figure was generated using Protter
(37), based on the Uniprot entry Q9UNQ0.
Table I Studied ABCG2 Variants
and Predicted Consequences of the
Amino Acid Changes




1216 G>A G406R rs142628079 0.01 (Damaging) 0.936 (Possibly damaging)
1291 T>C F431L NA 0.12 (Tolerated) 0.584 (Possibly damaging)
1322 G>A S441N rs758900849 0.55 (Tolerated) 0.091 (Benign)
1439 C>T P480L rs202192122 0.02 (Damaging) 0.959 (Probably damaging)
1465 T>C F489L rs192169063 0.07 (Tolerated) 0.180 (Benign)
1544 T>G M515R rs199806536 0.02 (Damaging) 0.933 (Possibly damaging)
1574 T>G L525R rs58818712 0 (Damaging) 1.000 (Probably damaging)
1582 G>A A528T rs45605536 0.02 (Damaging) 0.198 (Benign)
1624 A>G T542A rs35965584 0.62 (Tolerated) 0.149 (Benign)
NA= not available
a Consequences of the amino acid changes were predicted with the SIFT Human Protein online service (21) (http://sift.
jcvi.org/www/SIFT_enst_submit.html) and the Poly-Phen 2 service (22) (http://genetics.bwh.harvard.edu/pph2/) using
the human ABCG2 protein sequence (Uniprot entry Q9UNQ0) as the template.
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Cell Culture and Protein Expression
Sf9 cells were grown as a suspension culture in HyClone SfX
Insect cell medium supplemented with 5% FBS at 27°C. For
ABCG2 expression in Sf9 cells, the cells were harvested by
centrifugation at 1000 g for 10min (+4°C) 55 h after infection
with recombinant baculovirus and washed once with phos-
phate buffered saline. HEK293 cells were cultured in high-
glucose DMEM+GlutaMax-I supplemented with 10% fetal
bovine serum at 37°C, 5%CO2. Confluent cells were split 1:3
into T175 flasks and transduced the next day with ABCG2
WT, ABCG2 variant or eYFP baculovirus preparations. Cells
were incubated with the virus and 5 mM sodium butyrate for
72 h and then harvested by centrifuging at 3000 g for 15 min.
Vesicle Preparation
Crude membrane vesicles were prepared from Sf9 cells with
slight modifications to the method described by Chu et al. (25).
After washing twice with buffer containing 50 mM Tris-HCl
(pH 7.0) and 300 mM mannitol, cells were homogenized in
membrane buffer (50 mM Tris-HCl (pH 7.0), 50 mM man-
nitol and 2 mM EDTA) using a low clearance Dounce ho-
mogenizer for 40 strokes. Lysed cells were centrifuged at 800 g
for 10 min and membranes from the supernatant were
pelleted by centrifugation at 100 000 g for 75 min at + 4°C.
The pellet was suspended in membrane buffer. Similarly,
HEK293-vesicles were produced by resuspending the cell pel-
let in Tris-sucrose (TS) buffer (10 mM TRIS-HEPES,
250 mM sucrose, pH 7.4) and homogenizing using the
Dounce homogenizer as with Sf9 cells. The lysed cells were
centrifuged at 4000 g for 20 min at + 4°C and the resulting
supernatant was centrifuged for 90 min at 21,000 g, + 4°C.
Pellets were suspended with TS buffer. For bothHEK293 and
Sf9 vesicle preparations, the resuspended crude membrane
pellet was passed 20 times through a 27 gauge needle and
the protein concentration of all vesicle preparations was mea-
sured using the Bio-Rad protein assay based on the Bradford
method (Bio-Rad Laboratories Inc., Hercules, CA, USA).
Membrane vesicles were frozen in aliquots in liquid nitrogen
and stored at -80°C until use.
Transport Assays
Vesicular transport assays were performed using the rapid
filtration technique with MultiscreenHTS96-well, 1.0/
0.65 μm pore, glass fiber filter plates (MSFBN6B50)
Millipore (Molsheim, France) on a MultiScreenHTS vac-
uum manifold (Millipore). Sf9 transport assays were per-
formed by pre-incubating vesicles (total protein amount
50 μg) with ABCG2 substrate Lucifer Yellow (LY) in buff-
er (40 mM MOPS-Tris (pH 7.0), 60 mM KCl and 6 mM
MgCl2) for 5 min, then adding plain buffer (background
control) or ATP to a final concentration of 4 mM.
Reactions were terminated after 10 min using ice-cold
washing mix (40 mM MOPS-Tris (pH 7.0) and 70 mM
KCl) and immediately filtered. Filters were washed 5
times before drying. In the HEK293 transport assays, ves-
icles (total protein amount 15 μg) were incubated in TS
buffer in the presence of 10 mM MgCl2, 4 mM ATP or
AMP (negative control) and substrate at 37°C (LY) or
32°C (E1S). E1S was used as a mixture of
3H-labeled
and unlabeled compound at a final concentration of 1
μM. A 50 μM solution of unlabeled E1S was used to
pre-wet the f i l t e r p la te to decrease unspec i f i c
binding of 3H-labeled E1S. Reactions were stopped after
2 min (E1S) or 10 min (LY) using ice-cold TS buffer,
filtered and washed twice with 200 μl TS buffer.
For analysis, LY samples were eluted with 100 μl
0.1 M NaOH and neutralized with an equal amount of
0.1 M HCl. Fluorescence was detected using Varioskan
Flash (Thermo Fisher Scientific, Vantaa, Finland) at
430 nm excitation and 538 nm emission. E1S samples
were analyzed using scintillation counting with a Wallac
1450 Microbeta Trilux scintillation counter (Perkin
Elmer, Boston, MA, USA) after addition of 50 μl of
OptiPhase HiSafe 2 scintillation cocktail (Perkin Elmer)
to each well.
Western Blot
Vesicle samples (2 or 5 μg total protein per well) were
mixed with 2 x Laemmli buffer (Bio-Rad Laboratories)
and separated on a Mini-PROTEAN TGX Stain-Free
10% SDS-PAGE gel (Bio-Rad Laboratories). Samples
were subsequently transferred to a 0.45 μm nitrocellulose
membrane (Bio-Rad Laboratories). Membranes were
blocked with 5% (w/v) skimmed milk solution. Anti-
human ABCG2 mouse monoclonal antibody BXP-21
(ab3380, Abcam, Cambridge, United Kingdom) was used
at a 1:5000 dilution in 5%(w/v) skimmed milk in TBS-
Tween (0.1% Tween 20) to detect ABCG2. Goat Anti-
Mouse IgG Antibody, (H + L) HRP conjugate (Millipore,
Temecula, CA, USA) was used at 1:10 000 dilution in
2.5% (w/v) skimmed milk in TBS-Tween as the second-
ary antibody. Incubation time for both antibodies was 1
h. After washing with TBS-Tween and TBS, bands were
visualized with the Amersham ECL Prime Western blot-
ting detection reagent (GE Healthcare, Buckinghamshire,
United Kingdom) and the ChemiDoc XRS+ system (Bio-
Rad Laboratories). Image Lab software version 5.1 (Bio-
Rad) was used to quantify the band intensities. The Bio-
Rad Stain-free technology was used according to the
manufacturer’s instructions to normalize the data for total
protein content in lanes.
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Immunofluoresence Staining and Microscopy
HEK293 cells were seeded onto LabTek 8-well chamber
slides coated with 0.1 mg/ml poly-D-lysine at 0.2 *105 cells/
well. After 24 h incubation, cells were transduced using the
generated ABCG2 variant baculoviruses in the presence of
5 mM sodium butyrate. Cells were fixed the following day
using 4% PFA. A 0.5% saponin-PBS solution was used to
permeabilize cells and 10% goat serum in 0.1% saponin-
PBS was used for blocking for 1 h. Cells were labeled with
BXP-21 (1:2000) and subsequently with goat anti-Mouse IgG
(H + L)-Alexa Fluor 488 secondary antibody (A-11001,
ThermoFisher Scientific) at a 1:200 dilution. Normal mouse
IgG (1:400, Santa Cruz Biotechnology, Santa Cruz, CA,
USA) was used as a control. DAPI was used at 25 μg/ml to
visualize the nuclei. Cells were imaged using a Leica
DM6000B wide-field microscope (Leica Microsystems,
Wetzlar, Germany) at 40 x magnification. Staining and mi-
croscopy was performed on two separate batches of HEK293
cells transduced with the recombinant baculoviruses.
Data Analysis
ATP-dependent transport was calculated as the difference be-
tween the uptake in the presence and absence of ATP.
Transport activity in the ABCG2 variant vesicles was normal-
ized to the activity in wild-type ABCG2 vesicles. Statistical
significance in activity differences was evaluated using one-
way analysis of variance (ANOVA) with the Dunnett’s post
hoc test for multiple comparisons. The same test was also used
for the comparison of expression data from western blots.
Non-linear regression was used to calculate Vmax and Km
values for Lucifer Yellow kinetics in selected vesicle prepara-
tions. Statistical significance of the difference in Km and Vmax
values was evaluated using the extra-sum-of-squares F-test. In
all analyses, p-values below 0.05 were considered significant.
All statistical and regression analyses were performed using
GraphPad Prism 6.05 (GraphPad Software, San Diego, CA,
USA).
RESULTS
Nine variant forms of ABCG2 were successfully generated
and expressed in Sf9 and HEK293 cells. Transport activity
of the variants was evaluated using the vesicular transport
assay with probe substrates Lucifer Yellow (LY) and estrone
sulfate (E1S). The expression levels of the variants in the mem-
brane vesicle preparations were studied using western blotting
and the intracellular localization was evaluated in HEK293
cells using immunofluorescence microscopy.
Lucifer Yellow Transport in Sf9-ABCG2 Variant Vesicles
Eight out of the nine studied SNPs decreased LY transport at
50 μMbymore than 75% compared toWTABCG2 (Fig. 2a).
The exception was the alanine to threonine change at position
528, which decreased transport to 53%. The same pattern of
impaired transport for the variants was seen for E1S (data not
shown).The decrease in transport was verified with LY for the
least active variants (G406R, S441N, M515R and L525R) at
two additional concentrations (10 μM and 125 μM) (Fig. 2b).
Variants F431L, P480L, F489L, A528T and T542A were
subjected to more detailed studies of LY kinetics (Fig. 2c).
Although a trend forMichaelis-Menten kinetics could be seen,
reliable Km values could only be calculated for the least im-
paired variant (A528T), where the Km was 29.4 ± 4.67 μM.
The change in Km was not significantly different to the WT
ABCG2 that has a Km of 45.1 ± 4.85 μM, whereas the Vmax
of A528T was measured to be 26% of the WT, which is
significantly lower (p< 0.0001).
Lucifer Yellow and Estrone Sulfate Transport
in HEK293-ABCG2 Variant Vesicles
The transport activity of LY in the HEK293-ABCG2 variant
vesicles was in line with the results observed with Sf9 vesicles.
With 50 μM LY, transport by A528T was decreased to 50%
of the WT, but the transport activity of G406R, S441N,
L525R and T542A was abolished and severely impaired for
F431L, P480L and F489L (Fig. 3a). The variants showed sim-
ilar impaired transport activity of the physiological substrate
E1S (1 μM), although for the T542A variant we observed
transport of E1S, while no LY transport was detected
(Fig. 3b). The transport activity of A528T was similar with
both substrates. The Vmax of LY transport for the A528T
variant was 42% of WT ABCG2 (p< 0.001) (Fig. 3c). The
calculated Km values were higher than in Sf9 vesicles, 78.1
± 9.07 μM and 108 ± 22.0 μM for WT and A528T, respec-
tively, but as with the Sf9 preparations, the difference in Km
between WT and A528T was not significant.
Expression and Localization of ABCG2 Variants
Western blotting was used to study the expression levels of
ABCG2 variants in the membrane vesicles used for the activ-
ity studies. ABCG2 was detected using the BXP-21 antibody,
which reacts with the intracellular domains of ABCG2 (amino
acid residues 271-396) and therefore the presence of the stud-
ied amino acid changes are not expected to change the affinity
of the antibody. ABCG2 protein could be detected in all of the
Sf9 and HEK293 vesicle preparations of ABCG2 variants,
but the levels in HEK293 vesicles were lower than in Sf9
(Fig. 4). In Sf9 vesicles, six of the variants were expressed at
levels above 50% of WT, whereas 54% was the highest
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Fig. 2 Transport of Lucifer Yellow (LY) into Sf9-ABCG2 variant vesicles
(50 μg total protein/well). (a) Transport activity was assayed for all variants at
50 μM LY (b) Low transport activity was verified for the least active variants
(uptake ratio < 1.5 at 50 μM LY) at 10, 50 and 125 μM LY. Data in (a) and (b)
is presented as mean ATP-dependent transport (± SD) normalized to wild-
type (WT) ABCG2 from two separate batches of vesicles with reactions
performed in triplicates (c) Kinetics of LY transport. Incubation time with
ATP was 10 min. Data is presented as ATP-dependent uptake normalized
to the calculated Vmax of WT ABCG2. Points represent mean± SD of an
experiment performed in triplicates. Transport activity was significantly different
from WT ABCG2 in all preparations (p<0.0001) according to one-way
ANOVA analysis with the Dunnett’s post hoc test.
Fig. 3 Transport of 50 μM Lucifer Yellow (a) and 1 μM estrone-sulfate (b)
into HEK293-ABCG2 variant vesicles (15 μg total protein/well). Data in (a)
and (b) is presented as ATP-dependent uptake normalized to uptake in wild-
type (WT) ABCG2 vesicles. (c) Kinetics of Lucifer Yellow transport into
HEK293-ABCG2 WT and A528T vesicles (15 μg total protein/well). Data
is presented as ATP-dependent transport normalized to the calculated Vmax of
WTABCG2. Points represent mean± SD from experiments with two sep-
arate batches of vesicles with reactions performed in triplicates. In (a) and (b)
transport activity was significantly different fromWTABCG2 in all preparations
(p<0.0001) according to one-way ANOVA analysis with Dunnett’s post hoc
test.
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relative expression achieved with any of the variants in the
HEK293 vesicles. The expression of G460R, S441N and
M515R was significantly lower than the WT (p< 0.01) in
the Sf9 vesicles and only negligible amounts (<2% of WT) of
these three variants could be detected in the HEK293 vesicles.
All of the variants expressed in HEK293 cells showed signifi-
cantly lower expression levels compared to the WT
(p< 0.0001 or p< 0.001). No significant expression was seen
in the control vesicles for either Sf9 or HEK293 (p< 0.0001).
The size of the detected protein in Sf9-ABCG2 preparations
was approximately 70 kDa and slightly higher in the
HEK293-ABCG2 preparations possibly due to glycosylation
differences the mammalian and insect cells. Two distinct
bands could be seen in the Sf9-ABCG2 preparations of
S441N andM515R, whereas two bands could be seen in most
of the HEK293-ABCG2 vesicles.
Immunofluorescence microscopy was used to study the lo-
calization of ABCG2 variants in HEK293 cells. Wild-type
ABCG2 transduced in HEK293 cells showed typical mem-
brane staining when probed with the mAB BXP-21 (Fig. 5).
All samples transduced with ABCG2 variants showed some
ABCG2 expression in line with the results from western blot-
ting. Due to the nature of the baculovirus system, leading to
overexpression in affected cells, some ABCG2 was also
retained inside the cell. On the other hand, not all cells were
transduced by with the virus and expressed ABCG2. No ex-
pression of ABCG2 was detected in the control samples of
non-transduced cells or eYFP-transduced cells. Cell surface
expression, seen as an intensified band-like signal at cell edges,
could be observed for variants F431L, P480L, F489L, A528T
and T542A. On the contrary G406R, S441N, M515R and
L525R did not show an increased signal at the cell surface, but
instead tended to accumulate inside the cells or show low
expression in general. This corresponds to the low expression
seen in the western blot of HEK293-ABCG2 membrane ves-
icles of variants G406R, S441N and M515R.
DISCUSSION
In this study, nine naturally occurring variants predicted to be
localized in the transmembrane helices of ABCG2 were
expressed in both Sf9 insect cells and human derived
HEK293 cells. We used these two cell systems because despite
insect cells being widely used to study ABC transporters, Sf9-
ABCG2 preparations have decreased activity compared to
mammalian systems due to the lower cholesterol content in
Sf9 cell membranes (26). ABCG2 has been shown to localize
in cholesterol-enriched lipid rafts in cell membranes and ex-
hibit reduced transport activity with cholesterol depletion (27).
Moreover, insect cells are grown at 27°C and mammalian
cells at 37°C. It has been shown in several studies that expres-
sion at low temperatures may rescue certain protein variants
that were not expressed at 37°C (28). In addition to this, insect
Fig. 4 Expression of ABCG2 variants in vesicles produced from infected Sf9 or transduced HEK293 cells. (a) and (c) western blot analysis of ABCG2 expression
levels in isolated crude membrane vesicle preparations from Sf9-ABCG2 (a) and HEK293-ABCG2 cells (c) and corresponding control vesicles (mock and eYFP).
Representative blots are shown. (b) and (d) Expression levels of the variants based on band intensity quantification of western blots using the Image Lab software
from Bio-Rad for (b) Sf9-ABCG2 vesicles and (d) HEK293-ABCG2 vesicles. Band intensity was normalized using the total protein signal from lanes and results are
presented as the relative expression (%) compared to WT ABCG2. Bars represent the mean relative expression (± SD) from triplicate western blots. The
statistical significance of differences compared to the WTwas analyzed using one-way ANOVA with the Dunnett’s post hoc test. In (b) ** p<0.001, ****
p<0.0001 and in (d) p<0.0001 for all variants except F431L, where p<0.001.
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cells differ from mammalian cells with regards to post-
translational modifications such as glycosylation, which can
be detected in western blotting, but glycosylation differences
do not appear to affect ABCG2 ATPase activity (26). The
activity of the ABCG2 variants studied here relative to the
WT ABCG2 were very similar between the Sf9 and
HEK293 preparations, despite differences in the relative ex-
pression levels. Strikingly, we detected significantly decreased
transport of the two test substrates used in this study for all
nine variants. Five of these variants have previously been stud-
ied in vitro, while to our knowledge the activity of the variants
G406R, P480L, M515R and T542A has not previously been
characterized.
The F431L, S441N and F489L variants are the most
studied of the naturally occurring transmembrane SNPs.
The F431L and F489L variants have been reported to
have substrate dependent changes in transport activity;
methotrexate transport was not observed (29), while cells
carrying the variants still displayed resistance towards
other substrates like mitoxantrone and SN-38, even
though the resistance was reduced compared to the
WT ABCG2 (15,29,30). In contrast, the S441N variant
appears to be unable to transport any of the tested sub-
strates (9,12,15,16,29). These findings correlate well with
our results, as we observed some transport activity by the
F431L and F489L variants, while no transport activity
could be detected by the S441N variant. Moreover, the
F431L and F489L variants were expressed on the cell
surface in HEK293 cel l s as has been reported
(15,30,31), while the S441N variant was mainly found
intracellularly as expected from previous research
(12,15,16,32). Based on previous studies in Flp-In-293
cells, the S441N variant appears to be unstable, since
the presence of proteasomal proteolysis inhibitors was
able to rescue the protein and increase cell surface ex-
pression (32). The glycosylation pattern of S441N has
been reported to differ from WT ABCG2 and indeed
two bands were also seen for S441N in this study, with
Fig. 5 Localization of ABCG2 variants in HEK293 cells transduced with recombinant baculovirus. Immunofluorescence microscopy was used to study the
localization of ABCG2 variants as described in the Materials and Methods section. ABCG2 was detected using the BXP-21 antibody and AlexaFluor 488 (green)
and nuclei were stained with DAPI (blue).
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the main band in the Sf9 preparation being the lower
molecular weight form.
The L525R and A528T variants have not been as well
characterized. In a study by Skoglund et al. (17) both variants
were found at the plasma membrane, but the L525R variant
had significantly decreased expression and provided low resis-
tance towards tyrosine kinase inhibitors in a cellular assay,
while the A528T variant had similar expression levels com-
pared to the WT, but still displayed a decreased resistance
towards the tyrosine kinase inhibitors. We attained very sim-
ilar results, as L525R was unable to transport either of the
tested substrates, while A528T was the most active of the
tested variants, with a transport activity of approximately half
of the WT ABCG2. L525R was mainly retained inside the
cells and expression in the HEK293 membrane vesicles was
reduced by 75% compared to WT. Immunostaining showed
that A528T was correctly localized at the cell membrane, but
the expression in vesicles was roughly half of the WT. The
relatively high activity of the A528T variant in comparison to
the other transmembrane variants might be explained by the
localization of the SNP at the edge of the predicted fourth
transmembrane helix of ABCG2. If the topological prediction
is correct and the amino acid is not positioned within the
membrane, this substitution could be well tolerated since both
alanine and threonine are fairly small, neutral amino acids at
physiological pH.
In vitro functionality or expression of the variants
G406R, P480L, M515R and T542A has not been report-
ed previously. The transport activity of these variants was
significantly impaired in both Sf9 and HEK293 vesicles
for LY as well as E1S in the HEK293 vesicles. Low activ-
ity in membrane vesicles could be partly explained for
G406R and M515R by the retention of ABCG2 inside
the HEK293 cells seen in the immunofluorescence studies
and the western blot. However, it cannot be solely ex-
plained by this since transport was low also in Sf9 vesicles
despite a 39- and 45-fold higher relative expression level
in Sf9 than HEK293 vesicles for G406R and M515R,
respectively. G406 is the first of the glycines in the dimer-
ization motif G/A/SXXXG, which is conserved in the
ABCG-family (33). Mutation of either of the glycines to
leucine impaired substrate transport of ABCG2, while
substituting both glycines with alanine did not interfere
with the function (33). As the arginine is likely to disrupt
the molecular architecture in the transmembrane domain
of the protein to an even higher degree than the leucine
substitution, it was not unexpected that the G406R vari-
ant showed extremely low transport activity, similarly to
the M515R and the L525R variants. P480L and T542A
did localize at the cell membrane in HEK293 cells, al-
though the expression was lower than WT. The low ac-
tivity of these variants in the Sf9 vesicles, despite high
expression, points to functional defects of the protein.
Interestingly, the T542A substitution may display sub-
strate dependent effects on transport activity as it appears
able to transport E1S but not LY.
The online tools SIFT and Poly-Phen were used to predict
the consequences of amino acid substitutions on protein func-
tion (Table I) (21,22). Similar effects were predicted for seven
of the variants with both services while contrasting predictions
are given for the F431L and A528T substitutions. Both pro-
grams predicted that four of the nine transmembrane SNPs
are tolerated or benign. Since all of the studied variants de-
creased the apparent function of ABCG2 in vitro, it can be
concluded that these tools are not capable of predicting the
effect of all polymorphisms. Both programs correctly predict-
ed the disruptive effect of the substitutions to arginine, as well
as the proline to leucine substitution. However, the programs
failed to predict the damaging effect of substitutions where the
amino acid properties did not change as much, i.e. the phe-
nylalanine –leucine or threonine-alanine and even the serine-
aspargine substitution. The poor predictions might be due to
the localization of the SNPs in the transmembrane region,
which is not considered by the programs. The substitutions
are likely to cause improper folding of the protein due to the
membrane localization, which is less tolerant to changes in the
peptide sequence. Subsequently the misfolded protein is not
translocated to the plasma membrane, but remains
intracellular.
The global allele frequency of the studied variants is gen-
erally low (< 1%) based on genotyping studies in the Japanese
population (30,34–36) and the 1000 Genomes Project data-
base (1000genomes.org). This is the case for most ABCG2
SNPs, with the notable exceptions of the Q141K and V12M
variants. Due to the low frequency, the effect of the studied
variants is unlikely to be identified in genome-wide association
studies (GWAS) or clinical studies that are mainly suited to
recognize commonly occurring SNPs. However, the observed
significant decrease in the in vitro transport activity suggests
that patients harboring these variant alleles are at risk for
adverse effects of ABCG2 substrates or diseases linked to
ABCG2 function, such as gout. Since amino acid substitutions
in the transmembrane regions do not appear to be well toler-
ated, it is likely that other nonsynonymous SNPs localized to
the membrane helices have similar damaging effects on
ABCG2 function.
CONCLUSION
In conclusion, we have shown that nine naturally occurring
polymorphic variants of ABCG2 display significantly de-
creased transport function in the vesicular transport assay.
The damaging effect of variants G406R, P480L, M515R
and T542A is, to our knowledge, reported here for the first
time. The findings were confirmed by using two independent
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expression systems and they are in line with previous litera-
ture. Non-functionality could be explained for some variants
by altered expression patterns as shown by immunofluores-
cence microscopy. These results indicate that patients harbor-
ing these ABCG2 variant forms could suffer from unexpected
pharmacokinetic events of ABCG2 substrate drugs or have an
increased risk for diseases where ABCG2 is implicated. This
type of in vitro characterization of variants is important espe-
cially for variants with low allele frequencies which are difficult
to pick up in the limited sample populations used in pharma-
cogenetic studies.
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